RIBOCICLIB AND ENDOCRINE THERAPY (ET) IN HORMONE RECEPTOR-POSITIVE (HR plus ), HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2-NEGATIVE (HER-2) BREAST CANCER: THE MONALEESA CLINICAL TRIALS PROGRAM

被引：0

作者：

Campone, Mario ^{[1
]}

Tripathy, Debu ^{[5
]}

Chia, Stephen ^{[6
]}

Diaz-Padilla, Ivan ^{[3
]}

Lorenc, Karen R. ^{[4
]}

Miller, Michelle ^{[4
]}

Germa, Caroline ^{[4
]}

Conte, Pierfranco ^{[2
]}

机构：

[1] Inst Cancerol Ouest, Ctr Rene Gauducheau, St Herblain, France

[2] Univ Padua, Ist Oncol Veneto, Oncol & Gastroenterol Surg, Padua, Italy

[3] Novartis Pharma AG, Oncol, Basel, Switzerland

[4] Novartis Pharmaceut, Oncol, E Hanover, NJ USA

[5] Univ Texas MD Anderson Canc Ctr, Dept Breast Med Oncol, Houston, TX 77030 USA

[6] Univ British Columbia, Breast Tumour Grp, Vancouver, BC, Canada

来源：

关键词：

D O I：

10.1016/S0960-9776(17)30700-2

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

PO81

引用

页码：S50 / S50

页数：1